6 interventions graded Unsupported.
Epitalon (Epithalon)
Promoted in biohacker circles on the strength of unreplicated, low-quality single-lab studies, sold as an unregulated injectable. There is no credible independent human evidence it does anything for aging. This is at the far speculative end: high hype, minimal legitimate science, real sourcing risk.
Exosomes
A legitimate and promising research vehicle for cell-free signaling therapy that has been prematurely commercialized into unregulated IV, injected, and 'facial' exosome products sold for rejuvenation with zero efficacy evidence and documented infection harms drawing FDA warnings. The biology is real; the marketplace offerings are unproven and unsafe.
Gene Therapy (Follistatin, Telomerase/TERT)
Compelling mouse biology, but human 'evidence' consists of a founder's uncontrolled self-experiment and marketing by offshore biohacking ventures selling injections with no trials, no safety data, and a plausible cancer risk. Anyone offering follistatin or telomerase gene therapy for aging today is operating far outside validated medicine. Extreme skepticism warranted.
Plasma Dilution / Young Plasma
A vivid mouse phenomenon that spawned a predatory clinic industry selling young-blood infusions for thousands of dollars with zero human efficacy evidence, drawing an explicit FDA warning. The more interesting science (dilution/removal of bad factors) is still preclinical. Treat any young-plasma 'longevity' offering as a red-flag scam.
Stem Cell Therapies
A legitimate research area for specific diseases that has been aggressively hijacked by predatory clinics selling IV or injected 'stem cells' for anti-aging with no efficacy evidence and real, sometimes catastrophic, harms. Frontier, a site we also run, covers one example of that legitimate side: manufactured islet cells reversing type 1 diabetes in a first trial. There is no proven stem-cell therapy for aging itself. This is one of the highest-risk areas for consumer exploitation.
TA-65 / Telomerase Activators (Cycloastragenol)
Expensive, heavily marketed on the seductive telomere theory, with only small often-conflicted trials, an alternative (immune-cell-shift) explanation for its main claimed effect, no outcome data, and an unresolved cancer concern. High price, weak and contested evidence: among the poorer value propositions in this list.